Sfoglia per AUTORE
FENNELL DA
Collezione ASL Vercelli
Items : 8
The RON (MST1R)/MSP pathway is a potential therapeutic target in malignant pleural mesothelioma in Lung Cancer
2014
ASL Vercelli
Baird A-M; O'Byrne KJ; Easty D; Shiels L; Byrne A; Raeppel S; Soltermann A; Nonaka D; Fennell DA; Mutti L; Pass HI; Opitz I; Gray SG;
2013
ASL Vercelli
Manente AG; Valenti D; Pinton G; Jithesh PV; Daga A; Rossi L; Gray SG; O'Byrne KJ; Fennell DA; Vacca RA; Nilsson S; Mutti L; Moro L;
2013
ASL Vercelli
Manente AG; Valenti D; Pinton G; Jithesh PV; Daga A; Rossi L; Gray SG; O'Byrne KJ; Fennell DA; Vacca RA; Nilsson S; Mutti L; Moro L;
2013
ASL Vercelli
Manente AG; Valenti D; Pinton G; Jithesh PV; Daga A; Rossi L; Gray SG; O'Byrne KJ; Fennell DA; Vacca RA; Nilsson S; Mutti L; Moro L;
Inhibition of RON (MST1R) induces apoptosis and decreases the cellular migration and proliferation capacity of mesothelioma cells in Lung Cancer
2013
ASL Vercelli
Baird AM; O'Byrne KJ; Easty D; Soltermann A; Nonaka D; Fennell DA; Mutti L; Pass HI; Opitz I; Gray SG;
Advances in the systemic therapy of malignant pleural mesothelioma in Nature Clinical Practice Cardiovascular Medicine
2008
ASL Vercelli
Fennell DA; Gaudino G; O'Byrne KJ; Mutti L; van Meerbeeck J;
Bortezomib inhibits nuclear factor-?B-dependent survival and has potent in vivo activity in mesothelioma in Clinical Cancer Research
2007
ASL Vercelli
Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L;
Bortezomib inhibits nuclear factor-?B-dependent survival and has potent in vivo activity in mesothelioma in Clinical Cancer Research
2007
ASL Vercelli
Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L;